Integrins plays a role in the resistance of advanced cancers to radiotherapy and chemotherapy. In this study, we demonstrate that high expression of the α5 integrin subunit compromises temozolomide-induced tumor suppressor p53 activity in human glioblastoma cells. We found that depletion of the α5 integrin subunit increased p53 activity and temozolomide sensitivity. However, when cells were treated with the p53 activator nutlin-3a, the protective effect of α5 integrin on p53 activation and cell survival was lost. In a functional p53 background, nutlin-3a downregulated the α5 integrin subunit, thereby increasing the cytotoxic effect of temozolomide. Clinically, α5β1 integrin expression was associated with a more aggressive phenotype in brain tumors, and high α5 integrin gene expression was associated with decreased survival of patients with high-grade glioma. Taken together, our findings indicate that negative crosstalk between α5β1 integrin and p53 supports glioma resistance to temozolomide, providing preclinical proof-of-concept that α5β1 integrin represents a therapeutic target for high grade brain tumors. Direct activation of p53 may remain a therapeutic option in the subset of patients with high-grade gliomas that express both functional p53 and a high level of α5β1 integrin.
INTRODUCTION
Glioblastoma multiforme (GBM) are the most aggressive brain tumors and remain a challenge for oncologists. New therapies are urgently needed. Gene expression profiling of high-grade glioma revealed that genes of extracellular matrix components and their regulators are often affected in the patients. Fibronectin is overexpressed in glioblastoma versus normal brain (1) , and belongs to the cluster of genes associated with a more malignant phenotype (2, 3) . It has recently been shown that fibronectin knockdown delays tumor growth in a mouse glioma model (4) . The α5β1 integrin is a fibronectin receptor which was recently shown to have an important role in tumor progression (5), metastasis (6) and/or resistance to therapies (7) in lung, ovarian and breast cancer, respectively. Few works addressed directly the issue of α5β1 integrin in glioma. Through the use of non-peptidic α5β1 integrin antagonists and GBM cell lines, we previously demonstrated that α5β1 integrin may be a therapeutic target for these tumors (8, 9) and that concomitant addition of α5β1 antagonists sensitizes p53 wild-type (p53 wt) glioma cells to chemotherapeutic drugs (10). The presence of p53 mutations in high-grade glioma varied across GBM subtypes with 0, 21, 32 and 54 % in classical, neural, mesenchymal and proneural subtypes, respectively (11).There is increasing evidence that gliomas harboring a p53 wt resist to therapies through inhibitory pathways upstream of p53. Nutlin-3 belongs to the family of small-molecule inhibitors of the mdm2-p53 interaction (12). Nutlin-3 has been shown, alone or in combination with chemotherapeutic agents, to increase the degree of apoptosis in hematological malignancies (13) . Recent studies extended its therapeutic window for use in solid tumors (14, 15) .
The aim of this study was to investigate the role of α5β1 integrin in glioma resistance to Temozolomide (TMZ) chemotherapy using in vitro and in vivo models. We found Author Manuscript Published OnlineFirst on May 16, 2012 ; DOI: 10.1158/0008-5472. that a high expression of α5 subunit inhibited the TMZ-induced p53 pathway and that reactivation of p53 by nutlin-3a restores the sensitivity to TMZ by decreasing the expression of the α5β1 integrin. Finally we found that high α5 integrin gene expression is associated with a more aggressive phenotype in brain tumors and a decrease in survival of patients. Our results provide a clinical rationale for including α5β1 integrin-targeted therapy in a subpopulation of glioma patients.
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Author Manuscript Published OnlineFirst on May 16, 2012 ; DOI: 10.1158/0008-5472. Western blotting was carried out as previously described (10). Antibodies used were against α5 integrin Ab1928 (Millipore) or H104 (Santa-Cruz), β1 integrin Ab1952, GAPDH (Millipore,), p53 (BD Biosciences), or p53 pser15 (Cell Signaling).
Flow cytometry
After detachment with EDTA, cells were incubated for 30 min at 4°C under agitation in the presence of primary antibodies: anti-α5 integrin antibody IIA1 (BD Biosciences) and anti-β1 integrin antibodies (TS2/16 from Santa Cruz; 9EG7 and mab13 from BD Biosciences). After washing, cells were incubated for 30 min with secondary antibody (Alexa488-conjugated goat anti-mouse or rat, Jacksonimmuno Research). After washing, cells were analyzed using a FACS Calibur flow cytometer (BectonDickinson), and the mean fluorescence intensity characterizing surface expression of integrins was measured using the Cell Quest software.
Clonogenic assay
Clonogenic survival was determined as previously described (9).
Immunofluorescence
A total of 20 000 cells were seeded onto IBIDI µdishes coated with 10 µg/ml of poly-L-lysine. Cells were treated with nutlin-3a (10 µM) or with solvent during 24 hours before fixation with 4% PFA (10 min at room temperature) and then processed for α5 immunodetection (IIA1 antibody; 1/300). Confocal images were taken with a confocal microscope (Biorad 1024) equipped with a water immersion 60x objective. Images were collected using the Laser-Sharp 2000 software. pathologist to specify the tumor grade and the percentage of tumor cells. Only samples with at least 50% of tumoral cells (more than 50% of samples were > 70% tumoral cells) have been included in the study. Control tissues were obtained from epileptic surgery. The study was conducted in accordance with the Declaration of Helsinki. Realtime quantitative PCR was performed as described previously (17) . The threshold cycle (Ct) values for each gene were normalized to expression level of cyclophilin used as the housekeeping gene. Values were normalized relatively to the value obtained for one non tumoral control brain tissue which was included in each qPCR run. Immunological analysis of α5 protein expression was done as shown previously (17) .
Human biopsies

Human brain tumor data sets
Glioma gene expression datasets from two other cohorts were downloaded from the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/GEO, accession numbers GSE4271 and GSE4412). Micro array raw data were processed using R (version 2.10.1) (http://cran.r-project.org/), implemented with the BioConductor package (http://www.bioconductor.org). Estimates of the survival curves were computed using the Kaplan-Meier method. Univariate survival comparisons between the patients, according to low or high α5-integrin expression levels, were performed using a logrank test.
Human brain tumor xenografts
TCG4, TCG9 and TCG17 glioma xenograft models were obtained as previously described (18). Subcutaneous tumor growth was followed by measuring, three times We compared the effect of TMZ in U87MG cells depleted in (shRNA α5 ) or overexpressing (pcDNA α5 ) α5 integrin versus control cells (shRNA ns and pcDNA ctrl respectively). Because p53 is largely involved in chemotherapeutic drug effects and we showed previously that α5β1 integrin antagonists modulate the p53 pathway (10), we focused on TMZ-induced p53 activation. TMZ caused an increase in p53 protein in all cell lines but not significantly in pcDNA α5 cells (when normalized to GAPDH - As a first approach to confirm the role of the α5β1 integrin in TMZ chemoresistance in vivo, we used subcutaneous xenografted human brain tumors in nude mice. We selected three xenografts that exhibited a wild-type p53 and different levels of the α5 subunit. Kaplan-Meier analysis of the mouse survival suggest a relationship between α5 integrin level and resistance to TMZ (Figure 1d ), providing some evidence for a role of the α5 integrin in the chemoresistance of p53-wt-expressing tumors in vivo.
Activation of p53 by Nutlin-3a overrides the α5 integrin effects.
We next investigated whether high α5 also impacts on p53 activation by a nongenotoxic p53 activator in glioma cells. U87MG cells were treated with nutlin-3a. In contrast to the effects of TMZ, nutlin-3a stabilized p53, markedly increased the expression after nutlin-3a treatment was confirmed by specific immunostaining of the α5 subunit in U87MG-pcDNA ctrl and U87MG-pcDNA α5 cells and by flow cytometry analysis of the α5 subunit at the cell membrane ( Figure 3b) . A significant decrease in the α5 mRNA level was measured in U87MG pcDNA ctrl but not in pcDNA α5 cells, suggesting that nutlin-3a affected the α5 subunit at translational and posttranslational levels ( Figure 3c ). Nutlin-3a also decreased β1 at the protein and mRNA level in the U87MG cells, suggesting that both subunits of the α5β1 integrin are processed similarly after nutlin-3a treatment (Supplementary Figure S2) . However no effect on the β1 subunit expressed at the cell membrane could be detected after Nutlin-3a treatment (Supplementary Figure S2 and supplementary Table 1 ).
Nutlin-3a did not affect the endogenous α5 protein in p53 knockout LNZ308 cells unless p53 was re-expressed ( Figure 3d ). Nutlin-3a had no effect on α5 expression in U373 cells (Supplementary Figure S3) . Altogether, these data suggest that nutlin3a requires a functional p53 to decrease α5 expression, which in turn make the cells susceptible to the nutlin-3a-induced cell death. Data were confirmed at the protein level (Figure 4b ). Because the α5 subunit only dimerizes with β1, the data point towards a particular role for α5β1 integrin in glioma.
We analyzed the clinical data of grade III and grade IV patients. Log-rank analysis of the Kaplan-Meier survival curves demonstrated a significant survival advantage for patients with low α5-expressing glioma compared to high α5-expressing glioma.
These results were validated in two independent public datasets (2, 19) . Considering all three cohorts together, the group of high α5-expressing tumors included 39% of 
to down-regulation of the α5 integrin subunit in glioma cells. Based on our data, there seems to be a cross-antagonistic interaction between the α5 integrin and p53 that was only revealed by nutlin-3a, which may explain why this drug overcomes the prosurvival activity of the integrin. Our results are similar to recent data showing that nutlin-3a downregulates the oncogene DEK or overcomes the anti-apoptotic Bcl2 overexpression thus leading to cell apoptosis (25, 26).
In summary, we have shown for the first time that α5β1 integrin plays a critical role in resistance to TMZ therapy by interfering with the p53 pathway in high-grade glioma.
In addition, we have shown that activation of p53 by nutlin-3a represses the α5β1 integrin and we propose that such downregulation is an important mediator of nutlin3a cytotoxic activity. The relevance of our results is emphasized by the finding that α5 integrin gene overexpression is associated with decreased survival in high-grade glioma patients. Our data provide the rationale for a preclinical evaluation of p53 activators and/or α5β1 integrin antagonists in a subset of high-grade glioma which express a functional p53 and high levels of α5β1 integrin. 
Kaplan-Meier plots, considering the percentage of tumors that reached 4 V0 as the survival end point. 
